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Reaching Through the Genome
Rebecca S. Eisenberg
he past two decades have been a period of rapid evolution in the science
of biotechnology and therefore in patent strategies, if not in patent law
itself. Patent law takes a long time to catch up with science, and com-
mentators take a long time to catch up with the law, but patent lawyers don’t
have that luxury. They have to keep ahead of the game, figuring out claiming
strategies that allow their clients to capture the value of future discoveries. 
I want to discuss some of these strategies today.
The patenting of DNA sequences is hardly a new thing, but rather an
established practice that goes back at least two decades. It began with little fan-
fare and little controversy, in contrast to other first encounters of the patent 
system with new categories of invention in biotechnology and other fields. Con-
siderably more public controversy accompanied the allowance of patents on
microorganisms, animals, computer software, and business methods. The issu-
ance of patents in each of these areas provoked immediate opposition, along
with critical media commentary and congressional hearings.
In recent years we’ve seen similar attention focused on the practice of
patenting genes, but nothing like that happened when people first started
patenting genes in the early 1980s. At the time, public outcry over biotechnology
patents was focused on living organisms rather than genes. We didn’t see any
significant controversy over patenting DNA sequences until the advent of high-
throughput DNA sequencing in the early 1990s, when genomics started to look
more like information technology than like chemistry. By this point, patenting
genes was such a well-established practice that questions about whether DNA
should be patentable seemed quaint and out of touch.
Even in the early 1980s, when the courts were still wary of protecting
information technology,1 they viewed DNA as a molecule, a chemical, a com-
position of matter, rather than as information.2 Perhaps if the Patent and Trade-
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mark Office (PTO) and courts had coded DNA as a storage medium for infor-
mation, a metaphor that is more common in popular understandings today, the
outcome would have been different. Instead, paradoxically, for a while it was
far easier to patent nature’s information technology than it was to patent
human-made, electronic information technology.
Why was the patenting of genes so uncontroversial in the early days, and
why has it become so controversial since then? In the early days, patenting
genes looked like patenting drugs. Now it looks more like patenting scientific
information. We have a clear story about why we should issue patents on drugs.
It is less clear whether we want to issue patents on scientific information.
In fact, it was the scientific community, and not the usual antibiotech 
suspects, that first provoked public controversy over the patenting of DNA
sequences. The focus of the controversy was the filing of patent applications 
by the National Institutes of Health in the early ’90s on the first random gene
fragments (expressed sequence tags, or ESTs) coming out of the laboratory 
of Dr. Craig Venter while he was at NIH.3 But until the era of high-throughput
DNA sequencing, the scientific community did not complain about patenting
DNA.
The first generation of DNA sequence patents was directed toward genes
encoding proteins of interest. They typically claimed:
1. An isolated and purified DNA sequence.
2. A recombinant vector that includes the DNA sequence.
3. A transformed host cell that includes the vector.
These claims all covered tangible materials used to make pharmaceutical
products. The effect was similar to a patent on a drug, although the gene patent
was directed to the recombinant materials used in production of the protein
rather than to the protein product itself. The PTO and the courts treated these
patents the same way they treated patents on new chemical compounds. The
analogy may never have been perfect, but it worked, in the sense that it pro-
vided commercially effective patent protection that motivated investment in the
development of new products.
This was important because in the biopharmaceutical industry the patent
system does real work. In some industries, firms report that patents aren’t really
very important to their investment decisions, that other things matter more in
determining the profitability of innovation, such as being first to market, that
patents are just trading currency to get other patent holders to leave you alone.
That is not what one hears in the pharmaceutical industry. Empirical evi-
dence indicates that this is a field where patents really matter.4 Why? The stan-
dard account from the pharmaceutical industry is that new drugs cost a fortune
to develop, and there are many costly failures for each successful product. If
generic firms could compete and drive down prices on the successful products
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without incurring all the development costs on the full range of successful and
unsuccessful candidates, they would drive them out of business.
Early biotechnology firms saw themselves as “high-tech” pharmaceutical
firms developing therapeutic protein products rather than small molecule drugs.
They, too, wanted patents that would prevent free riders from destroying their
profits. Patents on genes promised to provide that protection and allowed these
new firms to raise capital and sometimes to get pharmaceutical firms to collab-
orate with them.
But in recent years the biotechnology and genomics industries have
become much more diverse in their research and business strategies. As the
Human Genome Project has generated vast quantities of DNA sequence infor-
mation, with biological significance yet to be determined, many firms have
emerged in a market niche that requires appropriating the value of information
resources for use in future research and product development. Research that
builds upon today’s bioinformatics platforms can contribute to the development
of products that are several steps removed from the genomic information base
that helped researchers on the path to discovery. It’s not obvious how to use
patents to capture the value that upstream research platform technologies con-
tribute to these discoveries. Firms are seeking strategies for reaching into the
revenues from end product sales, especially drug sales. The introduction of new
pharmaceutical products is typically the point at which bioscience starts to yield
real money.
Needless to say, the pharmaceutical industry is viewing these strategies
with concern. The industry has long relied on patents on drugs to make drug
development profitable, but patents on drugs are not the only patents that
accompany new drugs on the road to market these days. Patents on the prior
“upstream” inventions that explain disease pathways and mechanisms and iden-
tify potential drug targets impose costs on drug development. They are like so
many siphons at the feeding trough of new drugs, draining away profits in a lot
of different directions.
From a strategic perspective, the issue for upstream firms is how to use
intellectual property rights in advances that facilitate future research to capture
a share of the commercial value of the future discoveries that they facilitate, and
the issue for downstream drug developers is how to resist these strategies. From
a public policy perspective, we can recast the issue as how to allocate intellec-
tual property claims along the complex course of cumulative innovation in bio-
medical research.
When researchers identify the disease relevance of a gene or set of genes,
perhaps identifying a new drug target, can or should they be able to get patent
claims that dominate future products that bind that target?
Various strategies are available for achieving that goal. Each of these strate-
gies depends for its viability upon legal rules that might be interpreted or fine-
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tuned to promote, permit, inhibit, or forbid these strategies, depending on how
we feel about them as a normative matter.
One approach is called “reach-through licensing.” This is primarily a con-
tract strategy, although often the contract involves a license to use a patented
research platform technology or material. The basic idea is that the patent-
holder restricts access to a patented research-enabling technology to users that
agree, as a term in the license, to share a piece of the action in future products.
Sometimes the piece of the action takes the form of a royalty on future product
sales, and sometimes it takes the form of a license to use future inventions made
in the course of the research. Many institutions resist these strategies, but some
agree to them.5
Pharmaceutical firms will go to great lengths to avoid incurring reach-
through royalty obligations, such as inventing around a patent or even going
offshore to conduct drug screens. They will not sign a reach-through license
agreement unless they absolutely have to. Universities are rarely targeted for
reach-through royalties because they are unlikely to develop and sell products
on which royalties might be collected. But firms often seek grant-backs of
licenses to future inventions made in the course of university-based research as
a license term when they provide research tools to universities. For their part,
universities resist agreeing to grant-backs whenever possible. They view these
provisions as compromising their stewardship over future discoveries and
believe that firms should provide them with free access to research tools so that
they can advance the frontiers of knowledge.
Both pharmaceutical firms and universities believe that reach-through
rights overvalue the past contribution of tool providers relative to the work that
remains to be done by themselves as tool users in order to advance the course
of cumulative innovation. But for some institutions, particularly biotechnology
firms, reach-through license terms make sense. Not only do they ask others to
agree to pay them reach-through royalties, but they sometimes agree to pay
them themselves.
The diverse institutions comprising the biopharmaceutical research com-
munity do not easily arrive at agreement on reach-through rights. They consume
a lot of transaction costs in haggling about them, and if the haggling takes place
far enough upstream, when the profitable end point of the research looks spec-
ulative and far away, they might conclude it’s just not worth the costs of getting
to yes. This risk enhances the attractiveness of reach-through strategies that
don’t require ex ante agreements. Two such strategies have been getting atten-
tion: reach-through remedies and reach-through claiming.
A reach-through remedy is a damage award for infringement that is meas-
ured as a reach-through royalty on sales of products developed through unli-
censed use of a research tool. Janice Mueller has recently proposed such a remedy
as a modified “research exemption” from infringement liability.6 Under this pro-
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posal, researchers who use a patented tool to develop a commercial product
don’t need to get permission in advance, provided they give notice, but if their
research yields a product, they will be liable for reach-through royalties on that
product. If reach-through royalties become common in license agreements for
research tools, then they would arguably be an appropriate damage remedy
under current law, on the theory that they approximate the value to which a
willing licensor and licensee would have agreed. But in the present environ-
ment, with many would-be licensees putting up strong resistance to reach-
through royalties, such a remedy seems to substitute a court’s evaluation of fair
license terms for that of the market.
Another strategy is called “reach-through claiming,” which means issuing
patents that are broad enough to cover future discoveries enabled by prior
inventions. This strategy depends less on contract and more on patents. If the
claims of a patent cover future products, the owner does not need to get the
user to agree in advance to pay royalties on future product sales but can wait
until the user has a product ready to bring to market before sitting down to bar-
gain. Users that avoid patent owners at the research stage will still have to deal
with them later, perhaps from a weaker bargaining position.
Patent claims that reach beyond the technological accomplishments of the
patent holder are by no means unprecedented. It is common for pioneering
inventions that open up new fields (in which there is little prior art) to receive
broad patents that dominate future advances, including products that require
significant further R&D. An example of an early advance in the biotechnology
field that received broad reach-through claims is the Cohen-Boyer gene-splicing
technique patented by Stanford University. The patent claims covered not only
the enabling technology, subsequently put to use in many different academic
and industrial laboratories across a broad range of R&D problems, but also any
recombinant organisms created through use of the technology. The claims to
recombinant organisms reached through the disclosed technology to cover later-
developed starting materials used in recombinant production of proteins, giving
the patent owner a dominant claim over a whole generation of biotechnology
products.
But the history of patent law also includes many examples where the
courts have held that a broad claim on a pioneering invention simply proves too
much, including claims from such pioneering inventors as Morse and Edison.
Today the courts and the PTO seem to be viewing reach-through claims
in genomics with some skepticism, but that doesn’t stop inventors from continu-
ing to pursue such claims, and some of them may be succeeding.
A stylized example illustrates how these reach-through claims work. Suppose
a firm has identified a novel gene encoding a receptor, and based on similari-
ties to previously characterized genes, it appears to be a new member of a
known receptor family. Suppose further that based on what is known about
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other members of this family of receptors, the inventor plausibly speculates that
this new receptor might be a drug target. Let’s suppose the applicant wants to
patent:
1. The receptor itself, as an isolated and purified composition of matter.
2. A method of identifying a ligand that binds the receptor through screen-
ing procedures described in the specification.
3. Ligands identified by the screening method.
Is the applicant entitled to any of those claims? The applicant’s best hope
is for the first two claims—the claims to the isolated and purified receptor and
the drug-screening method. The biggest obstacle to obtaining these claims is the
requirement of utility (or industrial applicability, as it is known outside the
United States). In order to get a patent, the inventor must have a useful inven-
tion and must disclose how to use it. All the claims will fail unless the applica-
tion discloses a specific and substantial use for the receptor protein.7
Disclosure of a specific and substantial utility will be enough to permit the
inventor to claim the isolated and purified receptor and the screening method
to identify agonists. But it won’t permit him to reach through to claim the as-
yet-unidentified ligands. The primary obstacle to obtaining these reach-through
claims is the disclosure requirements of the patent laws. To patent an invention,
the inventor must provide a written description that is sufficient to enable a per-
son of ordinary skill in the relevant field to make and use it without undue
experimentation.8 For product claims to meet this standard, one must supply
information about the structure of products covered by the claim, and not just
their function.9 The hypothetical claims to ligands that bind the receptor fail to
meet this standard because all the applicant has disclosed is the function of the
molecules covered by the claim, without saying anything about their structure.
The Federal Circuit has been particularly tough in applying the written descrip-
tion requirement to biotechnology inventions,10 in contrast to its relatively light
touch on the utility11 and nonobviousness12 standards.
Nonetheless, technology has advanced in ways that give some firms a strategy
for addressing this written description problem. Researchers studying new pro-
teins can sometimes crystallize the protein and determine its three-dimensional
structure using X-ray crystallography. They can then obtain Cartesian coordinates
permitting visualization of the target on a computer screen, creating a 3-D
model of the target for use in designing ligands. Some patent claims have been
issued for methods of identifying candidate inhibitor compounds that involve
introducing crystal coordinates for a drug target into a computer program and
superimposing models of inhibitor test compounds to identify those that fit spa-
tially into an active site of the target.13
Might such an inventor also claim compounds identified through this com-
puter visualization technique? Perhaps. Although the written description require-
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ment is a potential problem, one might argue that the requirement is satisfied if
the crystal coordinates provide enough structural information linked to the func-
tion of binding the target to permit visualization of the molecules falling within
the scope of the claim. In other words, the applicant is not just claiming any
molecules that do the job but actually describing what such molecules would
look like.
Of course, the speculation might be wrong. Perhaps the shape of the
receptor in the environment in which it interacts (or not) with the rationally
designed compound is quite different than the shape found for the crystallized
protein. Or perhaps a prior art compound will turn out to fall within the scope
of the claims, rendering them invalid. A broad claim to a genus of compounds
fails to meet the novelty standard if even a single member of the genus was dis-
closed in the prior art, even if the properties of the prior art compound that
make it fall within the scope of the claim were merely inherent and not dis-
closed. Broad claims make big targets.
So while there are a lot of open questions yet to be resolved, there may
be some claiming strategies that allow upstream inventors to get reach-through
claims that will dominate future pharmaceutical products on the basis of pre-
liminary genomics and bioinformatics work.
How should we be thinking about these reach-through practices as a nor-
mative matter? Should the law permit or promote practices that allow early-stage
inventors to reach through to capture a share of the value of future discoveries?
Should it discourage or prohibit these practices?
Critics argue that reach-through rights over-reward those who rest on their
laurels at the expense of those who carry research forward. Moreover, mecha-
nisms that permit leveraging of patents on early discoveries into control of
future inventions raise potential antitrust concerns. To the extent that reach-
through rights continuously augment the number of rights-holders at the bar-
gaining table as cumulative research proceeds, they magnify risks of bargaining
failures in a potential “tragedy of the anticommons.” 14
On the other hand, reach-through rights may be a valuable way to permit
early innovators to capture the value that their discoveries contribute to subse-
quent research. Otherwise the stand-alone value of early innovations may be
too low, undermotivating the initial investment that is necessary to identify and
enable socially valuable research paths. A reach-through remedy may be a solu-
tion to the anticommons problem, permitting research to proceed without need
for constant negotiations over access to each proprietary input.
How one weighs these competing concerns depends upon how one views
the relative need for incentives at different points in the course of cumulative
innovation. If one worries more about the adequacy of incentives for early-stage
innovation and less about the adequacy of incentives for later-stage innovation,
then reach-through strategies make a lot of sense. On the other hand, if one
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worries more about the adequacy of incentives for downstream research and
product development, then reach-through strategies are cause for concern. Judi-
cial opinions about patent law reflect both of these perspectives.
Patent law sometimes rewards pioneers in a field with broad claims (and
a broad range of equivalents), while giving only narrower claims to those who
make follow-on improvements, even though the improvements may have more
stand-alone commercial value than the primitive versions of the invention devel-
oped by the pioneer. Suzanne Scotchmer has argued15 cogently that upstream
research is both riskier and less likely to have a high stand-alone value than
downstream research, which by definition is closer to market. She therefore
argues for giving broad rights to early innovators that allow them to force sub-
sequent improvers to deal with them. Giving a broad patent to the pioneer who
invents, say, a primitive sewing machine allows her to capture some of the 
follow-on value created by those who tweak the invention and make it more
user-friendly.
But one gets a very different picture of the relative contributions of early
and subsequent innovators from observing biotechnology and genomics
research. Of course, in biotechnology, as in other fields, there have been path-
breaking, pioneering discoveries that paved the way for lesser discoveries that
were more financially viable. But many of these discoveries were paid for by
NIH, raising questions about the need for strong patents to motivate and reward
the work that generates that sort of basic research. In recent years some private
firms have tried to figure out business models for generating biomedical
research information to provide a platform for downstream discovery, especially
in genomics, but often by the time private firms see such an opportunity, the
so-called upstream research has become relatively mechanical. For example,
when Celera decided they could take on the publicly funded Human Genome
Project and complete their own version of the human genome sequence,16 much
of the pathbreaking work had been done already. Although much work
remained, there was little question but that the job could be done. In this set-
ting, the “upstream” work of sequencing the genome looks relatively routine,
riskless, and uncreative compared with the “downstream” work of figuring out
what it all means and how to use the information to develop new diagnostic
and therapeutic products.
More generally, in the biomedical field, upstream research is relatively
cheap and heavily subsidized with public funding. Downstream research is rela-
tively costly and risky and relies primarily on private funding. This configura-
tion of risk and cost argues for focusing on motivating and rewarding down-
stream research more than upstream research.
But other factors would support the opposite intuition. The biotechnology
industry, already in its third decade, has mostly been unprofitable, while the
pharmaceutical industry over the same time period has been extremely prof-
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itable. Maybe this is partly because the pharmaceutical firms are smarter about
business than the biotechnology firms, but perhaps this gross disparity in the
bottom lines reflects in part a failure of the biotechnology industry to capture
the social value that they have contributed to the pharmaceutical industry. If that
is indeed what is going on, that cautions against disabling biotechnology firms
from using legal strategies to get their fair share.
Persistent bargaining failures in the biomedical research community over
the terms of access to research tools also caution against precluding reach-
through strategies. Universities, biotechnology firms, and pharmaceutical firms
describe these problems in different ways, each pointing the finger at the oth-
ers, but they all report difficulties in agreeing about what is fair and reasonable
when one institution provides another with resources that might facilitate future
discoveries. In this environment it makes little sense for the law to foreclose
options that might help the parties get to yes. Reach-through provisions can
help with two big problems in the licensing of research tools: valuation and
financing. If the parties cannot use reach-through provisions, they need to use
pay-as-you-go terms for access to research tools. This suits the pharmaceutical
industry just fine, because they have plenty of cash and would rather pay a rela-
tively small amount upfront than agree to share profits later. But reach-through
terms are more attractive to biotechnology firms that otherwise would be unable
to pay enough to compete with the pharmaceutical industry to get access to
research tools. In effect, reach-through agreements allow upstream and down-
stream biotechnology firms and universities to form joint ventures, sharing risks
without draining cash at the research stage.
Reach-through grant-back licenses—i.e., precommitments to license future
discoveries back to the provider of an upstream research platform—are more
troubling but may also be a valuable contract option. What makes these provi-
sions troubling is that they allow early innovators to exercise continuing control
over future research and perhaps to suppress new innovation. On the other
hand, such provisions may be a necessary defensive maneuver to permit early
sharing of research tools without having to worry about facilitating domination
by a competitor. Reach-through licenses can have a “copyleft” aspect to them,
disabling subsequent innovators who have benefited from access to a prede-
cessor’s research platform from monopolizing their own subsequent inventions.
Given that these provisions have the potential to enhance efficiency and
promote exchanges that are currently vexed by bargaining problems, it seems
unwise to preclude the use of reach-through provisions as terms in voluntary
agreements as a matter of law.
On the other hand, the case for reach-through royalties as a remedy for
patent infringement is far weaker. Such a remedy (which amounts to a com-
pulsory license in exchange for court-ordered payment of reach-through royal-
ties) has the advantage of permitting research to proceed without compelling
 
114 Rebecca S. Eisenberg
researchers to get licenses in advance, when the transaction costs may loom
large relative to the expected value of research that is far removed from com-
mercial payoffs. But they present a danger that a court-ordered remedy will be
too high or too low. The standard worry about compulsory licenses is that the
court-ordered remedy will be too low. In this setting there is also a risk that a
royalty rate determined ex post, when the research has proven successful and
valuable, will be significantly higher than an ex ante valuation arrived at be-
tween the parties. If reach-through royalties become common in licenses, the
terms of actual reach-through licenses negotiated ex ante will provide a bench-
mark to guard against overvaluation ex post. The law should follow, not lead,
actual contracting practices and award reach-through royalties if and when they
become common as a license term for research tools.
Reach-through claims raise all the problems of reach-through remedies
and more. Approved by the PTO in the course of ex parte patent prosecution,
patent claims are not tied even to a hypothetical agreement between prior and
subsequent innovators. Patent examiners who speak only to patent applicants
without hearing from future innovators may overvalue the importance of the
applicant’s invention relative to potential future discoveries. Multiple overlap-
ping claims, already common even with the PTO viewing reach-through claims
skeptically, will become much more common if reach-through claiming strate-
gies become more commonplace, giving multiple owners hold-up rights over
future products.
Patent law has a tradition of limiting patent protection to actual accom-
plishments and future variations that can be achieved through work that is rou-
tine and predictable. This is a sensible limitation that appropriately guides
patent examiners away from acceding to unreasonable requests for patent claims
that dominate future research that is itself fraught with risk and uncertainty.
There are good reasons for permitting prior innovators to use their intel-
lectual property to capture a fair share of the value that their discoveries con-
tribute to subsequent downstream innovation, but we can be more comfortable
with strategies that are negotiated in the market for licenses than with those that
are negotiated in the course of patent prosecution.
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